INVESTOR NEWS

Apr 20, 2026

Gentian Diagnostics renews long term faecal calprotectin partnership with Bühlmann Laboratories

Moss, 20 April 2026 Gentian Diagnostics, a fast-growing developer and manufacturer of high-quality diagnostic..

Apr 13, 2026

Gentian Diagnostics: Notice of annual general meeting

Gentian Diagnostics ASA’s annual general meeting will be held on Tuesday 5 May 2026 at 11:00 at the company’s..

Apr 10, 2026

Gentian Diagnostics ASA - Registration of share capital increase

Moss, 10 April 2026 Reference is made to Gentian Diagnostics ASA's stock exchange announcement on 12 March..

Mar 20, 2026

Gentian Diagnostics: Annual report 2025

Moss, 20 March 2026 Gentian Diagnostics has today published its annual report for 2025. The annual report and..

Mar 12, 2026

Gentian Diagnostics ASA – Mandatory notification of subscription of shares by primary insiders in Employee Share Purchase Program

Moss, 12 March 2026 Reference is made to Gentian Diagnostics ASA's (the "Company") stock exchange..

Mar 12, 2026

Gentian Diagnostics ASA – Employee Share Purchase Program and share capital increase

Moss, 12 March 2026 Gentian Diagnostics ASA (the "Company") has completed the offer of new shares to..

Feb 19, 2026

Mandatory notification of trade

Moss, 19 February 2026 Gentian Diagnostics ASA ("Gentian") has today been notified that the following..

Feb 13, 2026

Gentian Diagnostics ASA: Mandatory notification of trade

Moss, 13 February 2026 Gentian Diagnostics ASA ("Gentian") has today been notified that the following..

Feb 12, 2026

Mandatory notification of trade

Moss, 12 February 2026 Gentian Diagnostics ASA ("Gentian") has today been notified that the following..

Feb 12, 2026

Gentian Diagnostics: Key information relating to the proposed cash dividend

Moss, 12 February 2026 The Board of Directors of Gentian Diagnostics ASA proposes a dividend of NOK 0.60 per..